the arbutus biopharma corporation ( nafus ) is a large pharmacological drug product that has been developed in the past decade and has been able to improve the functional cure rate of chronic hepatitis b. we are excited to share our progress in advancing our strategy and we are encouraging by the progress we have made in these two phase two clinical trials to further support our goal. we will also provide a brief financial update and provide a discussion on the current status of our research and research efforts.